Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Suppression of breast cancer metastasis and extension of survival by a new antiestrogen in a preclinical model driven by mutant estrogen receptors.

Breast cancer research and treatment - 1 Jun 2020

Laws Mary J, Ziegler Yvonne, Shahoei Sayyed Hamed, Dey Parama, Kim Sung Hoon, Yasuda Mayuri, Park Ben Ho, Nettles Kendall W, Katzenellenbogen John A, Nelson Erik R, Katzenellenbogen Benita S

Abstract excerpt

PURPOSE: Many human breast tumors become resistant to endocrine therapies and recur due to estrogen receptor (ERα) mutations that convey constitutive activity and a more aggressive phenotype. Here, we examined the effectiveness of a novel adamantyl antiestrogen, K-07, in suppressing the growth of breast cancer metastases containing the two most frequent ER-activating mutations, Y537S and D538G, and in extending...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Ketones
Share to Liver Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to MCF-7 Cells

Share to Mice, Inbred NOD

Share to Mice, SCID

Share to Receptors, Estrogen

Share to Survival Rate

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 32277377
DOI: 10.1007/s10549-020-05629-y
PMCID: PMC7851760

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Suppression of breast cancer metastasis and extension of survival by a new antiestrogen in a preclinical model driven by mutant estrogen receptors.PMID 32277377Read ↗

Lasofoxifene as a potential treatment for therapy-resistant ER-positive metastatic breast cancer.Semantic proximity Read ↗

Effective combination therapies in preclinical endocrine resistant breast cancer models harboring ER mutations.Semantic proximity Read ↗

A Novel Model of Estrogen Receptor-Positive Breast Cancer Bone Metastasis with Antiestrogen ResponsivenessSemantic proximity Read ↗

Structurally Novel Antiestrogens Elicit Differential Responses from Constitutively Active Mutant Estrogen Receptors in Breast Cancer Cells and Tumors.Semantic proximity Read ↗

Integrated molecular and functional profiling identifies E0771 as a basal-like triple-negative breast cancer modelSemantic proximity Read ↗

Functional and molecular characterisation of EO771.LMB tumours, a new C57BL/6-mouse-derived model of spontaneously metastatic mammary cancer.Semantic proximity Read ↗

Hormonal modulation of ESR1 mutant metastasis.Semantic proximity Read ↗

An immune-humanized patient-derived xenograft model of estrogen-independent, hormone receptor positive metastatic breast cancer.Semantic proximity Read ↗

Estrogen receptor mutations found in breast cancer metastases integrated with the molecular pharmacology of selective ER modulators.Semantic proximity Read ↗

Reactivation of p53 by MDM2 Inhibitor MI-77301 for the Treatment of Endocrine-Resistant Breast CancerSemantic proximity Read ↗

Initiation of metastatic breast carcinoma by targeting of the ductal epithelium with adenovirus-cre: a novel transgenic mouse model of breast cancer.Semantic proximity Read ↗

Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.